Shares of Nuformix plc (LON:NFX – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as GBX 0.09 and last traded at GBX 0.10, with a volume of 4,712,799 shares. The stock had previously closed at GBX 0.10.
Nuformix Price Performance
The company has a 50-day moving average price of GBX 0.13 and a 200 day moving average price of GBX 0.18. The firm has a market capitalization of £2.87 million, a PE ratio of -3.75 and a beta of 1.53.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Read More
- Five stocks we like better than Nuformix
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
